Arbutus to Present Data on New LNP Formulations for Delivery of mRNA at the 2016 Controlled Release Society Conference
July 18 2016 - 5:00PM
In Vivo Data Support Improved Potency of New
Lipid CompositionsArbutus’ LNP Platform is the Leading Delivery
Solution for mRNA Therapeutics
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced presentation of data on new Lipid Nanoparticle (LNP)
compositions for messenger RNA (mRNA) delivery at the 2016
Controlled Release Society Annual Meeting and Exposition held July
17-20, 2016 in Seattle.
“Our proprietary LNP platform is the leading
nucleic acid delivery technology. We continue to improve LNP
formulations and have generated in vivo data demonstrating the
improved potency and tolerability associated with our new LNP
formulations for delivery of mRNA payloads. In addition, our
considerable clinical experience with the technology and our
ability to design, formulate and manufacture at scale can rapidly
enable our partners,” said Dr. Mark J. Murray, Arbutus’ President
and CEO. “Our primary goal is to develop a combination therapy to
cure chronic HBV. We believe that our dominant and comprehensive
intellectual property (IP) position in the field of LNP-enabled
nucleic acid delivery is an important asset that can generate
significant value through potential partnerships related to
delivery of mRNA therapeutics.”
About Arbutus Arbutus Biopharma
Corporation is a biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for patients
suffering from chronic hepatitis B infection. Arbutus is
headquartered in Vancouver, BC, Canada with offices in Doylestown,
PA, USA. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and
InformationThis press release contains forward-looking
statements within the meaning of the Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
and forward looking information within the meaning of Canadian
securities laws (collectively, “forward-looking statements”).
Forward-looking statements in this press release include statements
about presenting data on new Lipid Nanoparticle (LNP) compositions
for messenger RNA (mRNA) delivery at the 2016 Controlled Release
Society Annual Meeting and Exposition held July 17-20, 2016 in
Seattle; Arbutus’ LNP technology as a source of significant
potential non-dilutive funding for the company; discovering,
developing and commercializing a cure for patients suffering from
chronic hepatitis B infection; and the ability of our intellectual
property position in the field of LNP-enabled nucleic acid delivery
to generate significant value through potential partnerships
related to delivery of mRNA therapeutics.
With respect to the forward-looking statements
contained in this press release, Arbutus has made numerous
assumptions regarding, among other things: the effectiveness and
timeliness of preclinical and clinical trials, and the usefulness
of the data; regulatory approval; the continued demand for Arbutus’
assets; and the stability of economic and market conditions. While
Arbutus considers these assumptions to be reasonable, these
assumptions are inherently subject to significant business,
economic, competitive, market and social uncertainties and
contingencies. Additionally, there are known and unknown risk
factors which could cause Arbutus' actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements contained herein. Known risk factors
include, among others: anticipated preclinical and clinical trials
may be more costly or take longer to complete than anticipated, and
may never be initiated or completed, or may not generate results
that warrant future development of the tested drug candidate;
Arbutus may not receive the necessary regulatory approvals for the
clinical development of Arbutus' products; economic and market
conditions may worsen; and market shifts may require a change in
strategic focus.
A more complete discussion of the risks and
uncertainties facing Arbutus appears in Arbutus' Annual Report on
Form 10-K and Arbutus' continuous disclosure filings, which are
available at www.sedar.com and at www.sec.gov. All forward-looking
statements herein are qualified in their entirety by this
cautionary statement, and Arbutus disclaims any obligation to
revise or update any such forward-looking statements or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, except as required by law.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: acutler@arbutusbio.com
Helia Baradarani
Senior Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com
Media
Please direct all media inquiries to: media@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024